--One-year study continues to support positive safety and tolerability profile for ubrogepant--
--Two-month hepatic safety study in healthy volunteers demonstrated no signal of drug-induced liver injury--
--U.S. NDA filing for ubrogepant on track for early 2019--
PR Newswire
DUBLIN, Oct. 17, 2018